References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

nogr-329

Research Article

ЛЕКЦИЯ

LECTION

ЭРАДИКАЦИОННАЯ ТЕРАПИЯ HELICOBACTER PYLORI: НАСТОЯЩЕЕ И БУДУЩЕЕ

ERADICATION THERAPY OF HELICOBACTER PYLORI: PRESENT AND FUTURE

Сафина

Д. Д.

Safina

D. D.

diliarik@yandex.ru

Абдулхаков

С. Р.

Abdulkhakov

S. R.

noemail@neicon.ru

Абдулхаков

Р. А.

Abdulkhakov

R. A.

noemail@neicon.ru

Казанский (Приволжский) федеральный университет, Институт фундаментальной медицины и биологииРоссияKazan (Volga region) Federal University, Institute of Fundamental Medicine and BiologyRussian Federation

Казанский (Приволжский) федеральный университет, Институт фундаментальной медицины и биологии; Казанский государственный медицинский университетРоссияKazan (Volga region) Federal University, Institute of Fundamental Medicine and Biology; Kazan State Medical UniversityRussian Federation

Казанский государственный медицинский университетРоссияKazan State Medical UniversityRussian Federation

2016

20112016

0118493

2016

Сафина Д.Д., Абдулхаков С.Р., Абдулхаков Р.А.

Safina D.D., Abdulkhakov S.R., Abdulkhakov R.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/329

В последние годы частота успешной эрадикации H. рylori при применении существующих схем лечения продолжает снижаться, что объясняется в первую очередь появлением антибиотико-резистентных штаммов микроорганизма. Результаты последних исследований подтверждают факт, что стандартная тройная терапия становится неэффективным методом эрадикации H. pylori в связи с увеличением количества резистентных штаммов H.pylori. Уровень резистентности H. pylori к антибактериальным препаратам отличается как в разных странах, так в отдельных регионах в пределах одной страны. Таким образом, становится актуальным проведение исследований по изучению региональных особенностей устойчивости H. pylori к определенным антибактериальным препаратам с последующей разработкой схем эрадикационной терапии, эффективных в том или ином регионе. По-прежнему остается эффективной квадротерапия с препаратом висмута, позволяющая достичь хороших результатов. За последние годы было предложено несколько альтернативных схем эрадикации H. pylori, таких как последовательная, сопутствующая, гибридная терапии, включающих в себя три антибактериальных агента. В настоящее время эти схемы позволяют достичь хороших результатов при проведении эрадикации H. pylori.

Recently the rate of successful H. pylori eradication while using existing treatment regimens continues to decline, primarily due to the appearance of antibiotic-resistant strains of the microorganism. Recent studies confirm the fact that the standard triple therapy becomes ineffective method of H. pylori eradication, due to the increase of drug-resistant strains of H. pylori. H. pylori resistance level to antibacterial agents is not the same in different countries, as well as in certain regions within the same country. Thus, studing the regional features of H. pylori resistance to certain antibiotics with subsequent development of eradication regimens that are effective in particular region becomes extremely actual. Still bismuth containing quadruple therapy remains an effective method of H. pylori eradication, allowing to achieve good results. In recent years, several alternative schemes of H. pylori eradication were proposed, such as sequential, concomitant, hybrid therapy including three antimicrobial agents. Currently, these regimens allow to achieve quite high H. pylori eradication level.

эрадикационная терапияантибиотикорезистентностьстандартная тройная терапияквадротерапия с препаратом висмутапоследовательная терапиясопутствующая терапиягибридная схемаадъювантная терапия

Helicobacter pyloriHelicobacter pylorieradication therapyantibiotic resistancethe standard triple therapybismuth containing quadruple therapysequential therapyconcomitant therapyhybrid therapyadjuvant therapy

References1

Ford A. C., Axon A. T. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2010; 15 (Suppl 1): 1-6;

de Martel C., Parsonnet J. Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys. Digestive Diseases and Sciences. 2006; 51(12): 2292-2301;

Hunt R. H., Xiao S. D., Megraud F. et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. Journal of Gastrointestinal & Liver Diseases. 2011; 20(3): 299-304;

Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001; 49(3): 347-353;

de Martel C., Forman D., Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013; 42(2): 219-240;

Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6): 1374-1403;

Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection-the Maastricht IV. Florence Consensus Report. Gut. 2012; 61(5): 646-664;

Ивашкин В. Т., Маев И. В., Лапина Т. Л. и соавт. Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Росс. журн. гастроэнтерол., гепатол., колопроктол. 2012; 1 (22): 87-89;

Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И. и соавт. Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (V московские соглашения).Терапия. 2015; 2 (2): 9-18;

Graham D. Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59: 1143-1153;

Pacifico L., Osborn J. F., Bonci E. et al. Probiotics for the treatment of Helicobacter pylori infection in children. World J Gastroenterol. 2014; 20(3): 673-683;

Koletzko S., Richy F., Bontems P. et al. Prospective multicentre study on antibiotic resi stance of Helicobacter pylori strains obtained from children living in Europe. Gut. 2006; 55: 1711-1716;

Chinese Medical Association of Gastroenterology with Helicobacter pylori Study Group Research Group. Fourth National Consensus Report on Issues Helicobacter pylori infection. Wei Chang Bing Xue. 2012; 17: 618-626;

Lim S. G., Park R. W., Shin S. J. et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis. 2016; 48(4): 385-390;

Malfertheiner P., Selgrad M. Helicobacter pylori. Current Opinion in Gastroenterology. 2014: 30(6): 589-595;

Bang C. S., Baik G. H. Attempts to enhance the eradication rate of Нelicobacter pylori infection. World J Gastroenterol. 2014; 20(18): 5252-5262;

Рафальский В. В. Рекомендации маастрихт-4: выбор схемы эрадикации в эру роста антибиотикорезистентности H. pylori. Вестник практикующего врача. 2012, спецвыпуск 1: 27-33;

Дехнич Н. Н., Костякова Е. А., Пунин А. А. и соавт. Антибиотикорезистентность H. pylori: результаты микробиологического регионального исследования. Росс. журн. гастроэнтерол., гепатол., колопроктол. 2011; 21(2): 37-42;

Саблин О. А., Ильчишина Т. А. Проблема резистентности Helicobacter pylori к кларитромицину. Сonsilium Medicum, Гастроэнтерология. 2009; 2: 4-8;

Халикова А. Р., Файзуллина Р. А., Ахметов И. И. и соавт. Helicobacter pylori-ассоциированная инфекция у детей города Казани и факторы, оказывающие влияние на эффективность ее эрадикации. Гены и клетки. 2014; 9(3): 272-275:

Lazebnik L. B., Bordin D. S., Belousova N. L. et al. Frequency of site-specific mutations in the 23S RRNA gene of Helicobacter pylori in Moscow. Helicobacter. 2011; 16(1): 121;

Megraud F., Coenen S., Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013; 62: 34-42;

De Francesco V., Giorgio F., Hassan C. et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010; 19: 409-414;

Kanizaj T. F., Kunac N. Helicobacter pylori: Future perspectives in therapy reflecting three decades of experience. World J Gastroenterol. 2014; 20(3): 699-705;

Selgrad M., Meissle J., Bornschein J. et al. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol. 2013; 25: 1257-1260;

Ierardi E., Giorgio F., Losurdo G. et al. How antibiotic resistances could change Helicobacter pylori treatment: a matter of geography? World J Gastroenterol. 2013; 19: 8168-8180;

Liang X, Xu X, Zheng Q. et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013; 11: 802-807;

Song M., Ang T. L. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol.2014; 20: 1517-1528;

Fischbach L., Evans E. L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007; 26: 343-357;

McNicholl А.G., Tepes B., Gasbarrini A. et al. Pan-European Registry on H. pylori Management (HP-EuReg): Interim Analysis of First- and Second-Line Treatments. Gastroenterology 2016; 150(4): S875-S876;

Бордин Д. С., Янова О. Б., Абдулхаков Р. А. и соавт. Европейский регистр Helicobacter pylori (протокол Hp-EuReg): первые результаты российских центров. Терапевтический архив. 2016; 88(2): 33-38;

Yuan Y., Ford A. C., Khan K. J. et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013; 11; 12: CD008337;

Chey W. D., Wong B. C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102: 1808-1825;

Fock K. M., Katelaris P., Sugano K., et al. Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600;

Kim N., Kim J. J., Choe Y. H. et al. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009; 54: 269-278;

Sun Q., Liang X., Zheng Q. et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010; 15: 233-238;

Kim S. Y., Choi D. J., Chung J. W. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther. 2015; 6(4): 183-198;

Yang J. C., Lu C. W., Lin C. J. Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol. 2014; 20(18): 5283-5293;

Loyd R. A., McClellan D. A. Update on the evaluation and management of functional dyspepsia. Am Fam Physician. 2011; 83: 547-552;

Chuah S. K., Tsay F. W., Hsu P. I., Wu D. C. A new look at anti- Helicobacter pylori therapy. World J Gastroenterol. 2011; 17: 3971-3975;

Rinaldi V., Zullo A., Pugliano F. et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 1997; 11: 929-933;

Gisbert J. P., Calvet X., O’Connor A. et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010; 44: 313-325;

Gatta L., Vakil N., Vaira D., Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013; 347: f4587;

Kate V., Kalayarasan R., Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs. 2013; 73: 815-824;

Liou J. M., Chen C. C., Chen M. J. et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013; 381: 205-213;

Yoon H., Lee D. H., Kim N. et al. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 2013; 28: 1801-1809;

Ali Habib H. S., Murad H. A., Amir E. M., Halawa T. F. Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children. Indian J Pharmacol 2013; 45: 470-473;

Gatta L., Vakil N., Leandro G. et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009; 104(12): 3069-3079;

González E., Perez-Perez G. I., Maldonado-Garza H. J., Bosques-Padilla F.J. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014; 20(6): 1438-1449;

Stenström B., Mendis A., Marshall B. Helicobacter pylori - the latest in diagnosis and treatment. Aust Fam Physician. 2008; 37: 608-612;

Georgopoulos S., Papastergiou V., Xirouchakis E. et al. Nonbismuth quadruple “concomitant” therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. J Clin Gastroenterol. 2013; 47: 228-232;

Wu D. C., Hsu P. I., Wu J. Y. et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010; 8: 36-41;

McColl K. E. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010; 362: 1597-1604;

Gisbert J. P., Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011; 34: 604-617;

McNicholl A.G., Marin A. C., Molina-Infante J. et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut. 2014; 63: 244-249;

Jung S. M., Cheung D. Y., Kim J. I. et al. Comparing the Efficacy of Concomitant Therapy with Sequential Therapy as the First-Line Therapy of Helicobacter pylori Eradication. Gastroenterology Research and Practice. 2016; Volume 2016, Article ID1293649, 5 pages;

Mégraud F. H. pylori antibiotic resistance: prevalence, importance and advances in testing. Gut. 2004; 53: 1374-1384;

Hsu P. I., Wu D. C., Wu J. Y., Graham D. Y. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011; 16: 139-145;

Molina-Infante J., Romano M., Fernandez-Bermejo M. et al. 14-day, high-dose acid suppression, non-bismuth quadruple therapies (“hybrid” vs ”concomitant”) for Helicobacter pylori infection: a randomized trial. Gut. 2012; 61 (3): A47-49;

Molina-Infante J., Romano M., Fernandez-Bermejo M. et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013; 145: 121-128;

Sardarian H., Fakheri H., Hosseini V. et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter. 2013; 18: 129-134;

Zullo A., Scaccianoce G., De Francesco V. et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol. 2013; 37: 647-650;

De F. V., Hassan C., Ridola L. et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol. 2014; 63: 748-752;

Cammarota G., Martino A., Pirozzi G. et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther. 2004; 19: 789-795;

Savarino V., Zentilin P., Pivari M. et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther. 2000; 14: 893-900;

Liou J. M., Chen C. C., Chang C. Y. et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2013; 68: 450-456;

Gisbert J. P., Molina-Infante J., Marin A. C. et al. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection. Scand J Gastroenterol. 2013; 48: 652-656;

Gisbert J. P. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012; 2012: ID974594; 12 pages;

Cuadrado-Lavín A., Salcines-Caviedes J.R., Carrascosa M. F. et al. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother. 2012; 67: 2254-2259;

Di Caro S., Fini L., Daoud Y. et al. Levofloxacin/amoxicillin based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol. 2012; 18: 5669-5678;

Basu P. P., Rayapudi K., Pacana T., Shah N. J. et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011; 106: 1970-1975;

Gisbert J. P., Castro-Fernandez M., Perez-Aisa A. et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012; 35: 941-947;

Tay C. Y., Windsor H. M., Thirriot F., Lu W. et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther. 2012; 36: 1076-1083;

Ayala G., Escobedo-Hinojosa W. I., de la Cruz-Herrera C.F., Romero I. Exploring alternative treatments for Helicobacter pylori Infection. World J Gastroenterol. 2014; 20(6): 1450-1469;

Cindoruk M., Erkan G., Karakan T. et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007; 12: 309-316;

Song M. J., Park D. I., Park J. H. et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010; 15: 206-213;

Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009; 14(5): 97-107;

Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010; 32: 1069-1079;

Ahmad K., Fatemeh F., Mehri N., Maryam S. Probiotics for the treatment of pediatric Helicobacter pylori infection: a randomized double blind clinical trial. Iran J Pediatr. 2013; 23: 79-84;

Gokturk H. S., Demir M., Unler G. K. et al. Does long-term aspirin use have any effect on Helicobacter pylori eradication? Am J Med Sci. 2011; 342: 15-19.

The authors declare that there are no conflicts of interest present.